K
Kringle Pharma
Biotech & Life Sciences · Toyonaka, Japan · Founded 2001
Kringle Pharma is a late clinical-stage biopharmaceutical company focused on research and development of regenerative medicines MoreLess
Kringle Pharma is a late clinical stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines for patients suffering from incurable diseases. The company primarily focuses on conditions such as Acute Spinal Cord Injury and Amyotrophic Lateral Sclerosis (ALS). Operating in the global healthcare market, Kringle Pharma serves patients, healthcare providers, and medical institutions. The business model revolves around developing proprietary drug candidates through rigorous clinical trials and subsequently licensing these drugs to pharmaceutical companies for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from drug sales.
Keywords: biopharmaceutical, clinical stage, spinal cord injury, ALS, innovative medicines, drug development, healthcare, licensing, commercialization, incurable diseases.
Talent graph
Kringle Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
26 investors on Kringle Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Kringle Pharma has talent and traffic
Market sentiment
What the market is saying about Kringle Pharma
An AI-synthesized read of the highest-engagement posts about Kringle Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kringle Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.